ACADIA Pharmaceuticals Inc. to Post Q3 2025 Earnings of $0.19 Per Share, Zacks Research Forecasts (NASDAQ:ACAD)

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Zacks Research boosted their Q3 2025 earnings estimates for shares of ACADIA Pharmaceuticals in a research report issued on Wednesday, October 9th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of $0.19 for the quarter, up from their previous forecast of $0.18. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.52 per share. Zacks Research also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.78 EPS and Q3 2026 earnings at $0.32 EPS.

Other equities analysts have also issued reports about the stock. Morgan Stanley lowered shares of ACADIA Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $28.00 to $20.00 in a report on Wednesday, August 7th. Citigroup reduced their price objective on ACADIA Pharmaceuticals from $30.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Cantor Fitzgerald lowered their target price on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 13th. Finally, UBS Group lowered their price objective on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $25.56.

ACADIA Pharmaceuticals Stock Performance

NASDAQ:ACAD opened at $14.92 on Monday. The firm has a market cap of $2.47 billion, a P/E ratio of -1,492.00, a P/E/G ratio of 0.49 and a beta of 0.38. ACADIA Pharmaceuticals has a fifty-two week low of $14.31 and a fifty-two week high of $32.59. The firm has a 50-day simple moving average of $15.82 and a two-hundred day simple moving average of $16.32.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.02. ACADIA Pharmaceuticals had a return on equity of 6.89% and a net margin of 3.43%. The company had revenue of $241.96 million during the quarter, compared to analyst estimates of $235.95 million. During the same quarter last year, the company earned $0.01 EPS. The firm’s revenue for the quarter was up 46.4% on a year-over-year basis.

Insider Transactions at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, COO Brendan Teehan sold 9,534 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $145,679.52. Following the completion of the transaction, the chief operating officer now directly owns 52,177 shares in the company, valued at $797,264.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, COO Brendan Teehan sold 9,534 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $15.28, for a total value of $145,679.52. Following the sale, the chief operating officer now directly owns 52,177 shares in the company, valued at approximately $797,264.56. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark C. Schneyer sold 9,733 shares of ACADIA Pharmaceuticals stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total transaction of $148,720.24. Following the completion of the transaction, the chief financial officer now directly owns 43,735 shares of the company’s stock, valued at $668,270.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 51,014 shares of company stock valued at $779,494 over the last quarter. 28.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Park Place Capital Corp acquired a new position in shares of ACADIA Pharmaceuticals during the third quarter worth $25,000. Covestor Ltd raised its position in ACADIA Pharmaceuticals by 70.5% during the first quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 840 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of ACADIA Pharmaceuticals in the first quarter worth about $48,000. Stonepine Capital Management LLC acquired a new position in ACADIA Pharmaceuticals during the second quarter worth $81,000. Finally, Acadian Asset Management LLC acquired a new stake in ACADIA Pharmaceuticals during the 2nd quarter worth $111,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.